Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17559990 | 1.00 | KDM1A (0.42) | KDM1ARCOR1MAOAKDM1BRBP4 | |
| SCHEMBL17560095 | 0.91 | KDM1A (0.41) | KDM1ARCOR1MAOAKDM1BRBP4 | |
| SCHEMBL30388723 | 0.88 | GPR119 (0.45) | KDM1A | |
| SCHEMBL30388937 | 0.88 | GPR119 (0.45) | KDM1A | |
| SCHEMBL17574298 | 0.88 | GPR119 (0.45) | KDM1A | |
| SCHEMBL25060206 | 0.88 | GPR119 (0.45) | KDM1A | |
| SCHEMBL17574361 | 0.88 | GPR119 (0.45) | KDM1A | |
| SCHEMBL17560073 | 0.85 | KDM1A (0.45) | KDM1ARCOR1MAOA | |
| SCHEMBL17554393 | 0.85 | MAOB (0.41) | KDM1ARCOR1MAOAKDM1BKDM4E | |
| SCHEMBL17554392 | 0.85 | MAOB (0.41) | KDM1ARCOR1MAOAKDM1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189059-B1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2023-02-22 | — | — | EP | disclosed |
| US-10183952-B2 | Thienopyrroles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2019-01-22 | — | — | US | disclosed |
| US-20170260197-A1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2017-09-14 | — | — | US | disclosed |
| EP-3189059-A2 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | Istituto Europeo di Oncologia S.r.l. (IT) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034946-A2 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2016-03-10 | — | — | WO | disclosed |
| EP-2993175-A1 | Thienopyrroles as histone demethylase inhibitors | IEO - Istituto Europeo di Oncologia Srl (IT) | 2016-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183952-B2 | Thienopyrroles as histone demethylase inhibitors | KDM1A, KDM1B, KDM3A | KDM1A 1/4885RCOR1 116/4885MAOA 2008/4885 |
| US-20170260197-A1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | KDM1A, KDM1B, KDM3A | KDM1A 1/4885RCOR1 116/4885MAOA 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.